Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 97.00% is 19% above its 5-year average of 81.82%, near the high end of its 5-year range (0.00%–100.00%).
45.50% above its 12-month average of 66.67%.
Reported quarterly gross margin; no daily interpolation. Q4 FY2025 (2025-12-31): 0.00%.
GROSS MARGIN
97.00%
GROSS MARGIN AVG TTM
66.67%
GROSS MARGIN AVG 3Y
85.71%
GROSS MARGIN AVG 5Y
81.82%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+45.50%
CURRENT VS 3Y AVG
+13.17%
CURRENT VS 5Y AVG
+18.56%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.91%
median of 560 covered companies
CURRENT VS SECTOR MEDIAN
+126.05%
vs the sector median at left
Market Cap
$55.94M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
50.00%
5Y Avg
33.33%
Market Cap
$54.48M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$53.01M
Gross Margin
-29.12%
TTM Avg
13.64%
3Y Avg
-48.92%
5Y Avg
-105.92%
Market Cap
$51.06M
Gross Margin
N/A
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
16.67%
Market Cap
$57.33M
Gross Margin
41.51%
TTM Avg
45.14%
3Y Avg
44.16%
5Y Avg
37.16%
Market Cap
$51.72M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apollomics, Inc. (APLM) | $54.90M | 97.00% | 66.67% | 85.71% | 81.82% |
| Connect Biopharma Holdings Limited (CNTB)vs › | $55.94M | 100.00% | 100.00% | 50.00% | 33.33% |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $54.48M | 0.00% | 0.00% | 0.00% | 0.00% |
| ImageneBio Inc (IMA)vs › | $53.01M | -29.12% | 13.64% | -48.92% | -105.92% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.06M | N/A | 50.00% | 25.00% | 16.67% |
| Spectral AI, Inc. (MDAI)vs › | $57.33M | 41.51% | 45.14% | 44.16% | 37.16% |
| Microbot Medical Inc. (MBOT)vs › | $51.72M | 0.00% | 0.00% | 0.00% | 0.00% |
| biote Corp. (BTMD)vs › | $50.28M | 71.46% | 70.99% | 69.42% | 67.35% |
| eXoZymes, Inc. (EXOZ)vs › | $55.97M | 0.00% | 0.00% | 0.00% | 0.00% |
| INmune Bio, Inc. (INMB)vs › | $51.28M | 100.00% | 100.00% | 100.00% | 100.00% |
Gross Margin
97.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 0.00% |
| 2025-06-30 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-06-30 | 100.00% |
| 2023-12-31 | 100.00% |
| 2023-06-30 | 100.00% |
| 2022-12-31 | 100.00% |
| 2022-06-30 | 100.00% |
| 2021-12-31 | 100.00% |
| 2021-06-30 | 100.00% |
| 2020-12-31 | 0.00% |
| 2020-06-30 | 108.60% |
| 2019-12-31 | 0.00% |
| 2019-06-30 | 0.00% |
